Is serum HER2 ECD a predictive biomarker for response to trastuzumab in advanced gastric cancer?

J Gastroenterol. 2016 May;51(5):506-7. doi: 10.1007/s00535-016-1184-2. Epub 2016 Feb 18.

Authors

Takeshi Yamada¹, Yoshiyuki Yamamoto², Toshikazu Moriwaki², Ichisnosuke Hyodo²

Affiliations

¹ Department of Gastroenterology, University of Tsukuba, Tsukuba, Japan. t.yamada718@md.tsukuba.ac.jp.
² Department of Gastroenterology, University of Tsukuba, Tsukuba, Japan.

PMID: 26891910
DOI: 10.1007/s00535-016-1184-2

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Agents / therapeutic use
Biomarkers, Tumor / blood
Humans
Stomach Neoplasms / drug therapy*
Trastuzumab*

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Biomarkers, Tumor
Trastuzumab